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Abstract
Identifying rare variants that are responsible for complex disease has been promoted by advances in sequencing
technologies. However, statistical methods that can handle the vast amount of data generated and that can
interpret the complicated relationship between disease and these variants have lagged. We apply a zero-inflated
Poisson regression model to take into account the excess of zeros caused by the extremely low frequency of the
24,487 exonic variants in the Genetic Analysis Workshop 17 data. We grouped the 697 subjects in the data set as
Europeans, Asians, and Africans based on principal components analysis and found the total number of rare
variants per gene for each individual. We then analyzed these collapsed variants based on the assumption that rare
variants are enriched in a group of people affected by a disease compared to a group of unaffected people. We
also tested the hypothesis with quantitative traits Q1, Q2, and Q4. Analyses performed on the combined 697
individuals and on each ethnic group yielded different results. For the combined population analysis, we found
that UGT1A1, which was not part of the simulation model, was associated with disease liability and that FLT1,
which was a causal locus in the simulation model, was associated with Q1. Of the causal loci in the simulation
models, FLT1 and KDR were associated with Q1 and VNN1 was correlated with Q2. No significant genes were
associated with Q4. These results show the feasibility and capability of our new statistical model to detect multiple
rare variants influencing disease risk.
Background
The identification of common variants associated with a
disease has been successful through the use of genome-
wide association studies (GWAS). However, most of the
associated single nucleotide polymorphisms (SNPs) have
small effect sizes and small proportions of heritability
[1]. In addition, some GWAS have failed to detect dis-
ease causal variants because of the strong assumption
that common variants contribute to an increase in risk
of common diseases (the common disease/common var-
iant hypothesis) [2]. Recently several rare variants have
been identified that confer a substantial risk for autism,
mental retardation, and schizophrenia [1]. These obser-
vations support a hypothesis that rare variants could be
the primary drivers of common diseases (the common
disease/rare variant hypothesis). This hypothesis
assumes that a significant proportion of the inherited
susceptibility to relatively common human disease may
be caused by the accumulation of the effects of a series
of low-frequency variants acting dominantly or addi-
tively to increase the relative risk for disease [2].
GWAS have been designed to achieve statistical power
for variants occurring in more than 5% of the general
population, and they provide little information about
relatively common variants with frequencies between 1%
and 5%. However, recent advances in next-generation
sequencing technologies and ventures, such as the 1000
Genomes Project, allow for the introduction of novel
rare variants that most likely occur in less than 5% (or
even in less than 1%) of one or more major human
populations. Although knowledge of these novel rare
v a r i a n t sc a nb eu s e di na s s o c i a t i o ns t u d i e so fc o m m o n
diseases, statistical analyses are challenging because the
ordinary SNP-by-SNP methods that are suited for
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ciation because of the extremely low frequency of each
variant [3]. Furthermore, statistical power is dramatically
reduced when we take into account correction for mul-
tiple tests. Therefore one of the key challenges in rare
variant association studies is how to capture (i.e., group)
the variants by genomic region to overcome the reduc-
tion in power experienced in ordinary SNP-by-SNP
methods.
In this paper, we collapse rare variants within a gene
in two ways: first, using rare variants of all SNPs, and,
second, using only rare variants of nonsynonymous
SNPs to see the functional effect on disease traits. We
then test for association of the rare variants with disease
traits under the hypothesis that the number of rare var-
iants within a gene is correlated either positively or
negatively with the traits. To perform this test, we apply
a novel statistical approach, called zero-inflated Poisson
regression models, which provides flexibility for the
excess of zeros caused by the extremely low frequency
of the variants [4]. We test 3,205 genes under two sce-
narios: one including a single group made up of all 697
subjects after adjusting for population substructure and
the other involving separating the subjects into three
ethnic groups based on principal components analysis
and geographic information. Results from these analyses
show the feasibility of using this new statistical model to
take into account the excess of zeros and to detect mul-
tiple rare variants responsible for disease risk.
Methods
Data
The genotypes for 24,487 exonic SNPs from 3,205 genes
included in the 1000 Genomes Project were distributed
by Genetic Analysis Workshop 17 (GAW17) [5]. The
SNPs consist of synonymous SNPs and nonsynonymous
SNPs. Data for 697 individuals was provided for analysis
and consisted of seven population groups: European
Americans, Tuscans (from Italy), Yoruba, Luhya (from
Kenya), Han and Denver Chinese, and Japanese. For
phenotypes, 200 replicate simulations were carried out
to give disease status (1 = affected, 0 = not affected) and
three quantitative traits (Q1, Q2, Q4) for each indivi-
dual. Information such as smoking status, sex, and age
of each individual was also available.
Collapsing rare variants
Analysis of single SNPs with extremely low frequency
leads to a reduction in statistical power, especially when
correcting for multiple comparisons. To overcome this
obstacle, we consider collapsing multiple rare variants
into a single gene-based variant. The advantages of this
strategy are that it reduces the number of tests and that
it enhances the variability of the variants as mutational
signals [6]. Assume that N is the total number of indivi-
duals, m is the total number of genes, and nj is the total
number of SNPs on the jth gene. We define an indicator
variable for the genotype of the kth SNP of the jth gene
for the ith individual as follows:
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Statistical models
For each gene, we applied a zero-inflated Poisson model
based on the results of collapsing the variants. Because
our method is a gene-based approach, subscript j is
omitted for convenience. The statistical models are:
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is the total number of rare variants at the jth gene for
the ith subject. Parameters p =( p1, p2, …, pN)
T and μ =
(μ1, μ2, …, μ N)
T are modeled by means of canonical
link generalized linear models as:
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where Xi is an indicator variable given by Xi =1f o ra
case individual and Xi = 0 for a control individual in
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and smoking status, respectively. PCSip is the principal
component score obtained by multidimensional scaling
(MDS) analysis of identical-by-state pairwise distances
in PLINK. For a quantitative trait analysis, the statistical
model uses the same framework but replaces Xi with
the quantitative trait (Q1, Q2, Q4) value for each sub-
ject. We test b1 = 0 for the association of each trait. All
statistical analyses were performed using SAS software.
Analysis procedure
Association studies are sensitive to population stratifica-
tion. The results often vary as a result of differences in
minor allele frequency, linkage disequilibrium patterns,
causal pathways, or environmental exposures. To mini-
mize the effects of such variability, we must examine
the relationship between genetic variants and disease
traits within ethnicities. For the GAW17 data set we
analyzed, we performed an MDS analysis based on all
the available exonic SNPs using PLINK to estimate
population substructure and to detect outliers. The
results of the MDS analysis classified individuals as
belonging to one of three major ethnic groups: Eur-
opean Americans and Tuscans in Italy were grouped
together as Europeans, Yoruba in Nigeria and Luhya in
Kenya were grouped as Africans, and Japanese and Chi-
nese in both Beijing and Denver were grouped as
Asians. These populations were both geographically and
genetically similar. In addition, we performed principal
components analysis on all exonic SNPs using Eigenstrat
[7] and obtained the first 10 main eigenvectors, which
can track membership in populations with 99.9% accu-
racy [7]. We control the 10 eigenvectors for subtle sub-
population stratification caused by the seven original
populations in the statistical model.
We then performed genotype-phenotype association
analysis under two scenarios: (1) analyzing the three
ethnic groups separately to account for different minor
allele frequencies among the SNPs and (2) analyzing all
697 individuals together in one large group to compare
the results. We adjusted for the first 10 eigenvectors in
both cases to control for subtle subpopulations, as noted
previously. For each subject in a given group, we first
indicated the presence of the minor allele for each SNP
and then collapsed multiple rare variants within each
gene for both the all-exonic-SNPs model and the nonsy-
nonymous-SNPs-only model, as previously described.
We applied the zero-inflated Poisson model to identify
significant genes associated with the disease trait and
quantitative traits. p-values for 3,205 autosomal genes
were obtained from each analysis. The estimated p-value
threshold was 1.56 × 10
−5 (= 0.05/3,205) after control-
ling for multiple tests. Next, we analyzed the 200 repli-
cates provided in the data set to calculate the power at
a significance level of 0.05 and 1.56 × 10
−5 in order to
compare our results with the true genes in the GAW17
answers.
Results
MDS analysis revealed three ethnic groups formed by
the seven populations in the data set. Five outliers were
found among the 697 subjects and were subsequently
removed, leaving the total number of individuals used in
t h ea n a l y s i sa t6 9 2 .B r o k e nd o w nb ye t h n i cg r o u p ,w e
found 215 Africans, 321 Asians, and 156 European indi-
viduals (data not shown) [7]. To determine whether
genetic structure differed across the ethnic groups, we
estimated the minor allele frequencies of the SNPs
found on two randomly selected genes. Table 1 shows
how the minor allele frequencies and rare variants
found in each gene vary greatly across the three ethnic
groups. To account for these differences, we collapsed
the rare variants within a gene and performed the analy-
sis for each ethnic group separately.
Table 2 shows genes that were significantly associated
with disease liability and quantitative traits Q1, Q2, and
Q4 based on the pooled data set of 692 individuals. For
each of these genes, the table displays the percentage of
replicates, out of 200, whose p-values were less than
0.05 before adjusting for multiple tests or less than 1.56
×1 0
−5 after adjusting for multiple tests. Genes that
were significant at the 5% significance level in at least
Table 1 Minor allele frequencies of SNPs within two randomly selected genes
Gene Chromosome SNP Function Minor allele Minor allele frequency
All* Europeans Asians Africans
CFH 1 C1S8678 Nonsynonymous A 0.341 0.032 0.579 0.982
C1S8682 Synonymous C 0.001 0 0 0.005
C1S8684 Synonymous A 0.311 0.923 0.106 0.964
C1S8686 Nonsynonymous C 0.325 0.942 0.134 0.959
SMAD7 18 C18S2642 Synonymous C 0.006 0 0.022 0
C18S2643 Synonymous A 0.009 0 0.034 0
C18S2648 Synonymous T 0.006 0 0.028 0
* All 697 individuals were used to calculate the minor allele frequency.
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boldface are causal genes in the simulation model, and
those not in boldface are examples of false-positive asso-
ciation that were seen frequently across replicates.
Through the disease liability analysis, we identified
four unique genes with a replication rate of more than
70% when using all exonic SNPs and eight unique genes
when using only nonsynonymous SNPs. UGT1A1,
which was not part of the simulation model, was
detected in both cases. Analysis of quantitative traits Q1
and Q2 identified five unique genes when including all
exonic SNPs and two unique genes when including only
nonsynonymous SNPs. FLT1,o n eo ft h et r u ec a u s a l
genes in the simulation model, was associated with Q1
in both cases with a replication rate of more than 90%
after adjusting for multiple tests. PTPN11,w h i c hw a s
not a true causal gene in the model, was identified in
association with disease liability, Q1, and Q2 when ana-
lyzing all exonic SNPs but not when analyzing only non-
synonymous SNPs. Also, based on a replication rate
criterion of 70%, we found no significant genes asso-
ciated with Q4 in any of the scenarios.
Table 3 lists the genes that are significantly associated
with disease liability for each ethnic group when using
all exonic SNPs. As illustrated, many of the genes that
were significantly associated in a high percentage (>70%)
of replicates in one particular ethnic group were not
detected in the combined sample. All these associations
were false-positive results. Tables 4 and 5 provide the
power to detect significant association of genes that
were in the GAW17 simulation models. Three genes
(FLT1 for Q1 and disease liability, KDR for Q1, and
VNN1 for Q2) were detected with moderate to high
power in either the all-exonic-SNPs or the nonsynon-
ymous-SNPs-only analysis. PTK2 was associated with
disease liability with a power of 50% in the nonsynon-
ymous-SNPs-only analysis.
Discussion and conclusions
It is well known that not all coding rare variants within
coding portions of genes are causative, and grouping
them together regardless of their functional effect may
produce false-positive errors. Therefore successful use of
collapsing strategies increases the power to detect
potential causative variants in association studies. We
have applied a zero-inflated Poisson regression model to
two separate collapsing methods: one in which we used
all available exonic SNPs and the other in which we lim-
ited the data to nonsynonymous SNPs alone. Based on
these analyses, we found that four unique genes were
associated with disease liability and five were in associa-
tion with quantitative traits Q1 and Q2 when collapsing
all exonic SNPs within a gene. When collapsing only the
nonsynonymous SNPs within a gene, we found eight
unique genes in association with disease liability and
two unique genes from Q1 and Q2. UGT1A1 and FLT1
were the only genes detected by both analyses. The dif-
ferences between these results show how the detection
Table 2 Genes associated with disease liability, Q1, and Q2 for the pooled populations at the significance levels of
0.05 and 1.56 × 10
−5
Trait All SNPs (nonsynonymous and synonymous) Nonsynonymous SNPs
Gene Replicates significant
at 0.05 (%)
a
Replicates significant at
1.56 × 10
−5 (%)
b
Gene Replicates significant
at 0.05 (%)
a
Replicates significant at
1.56 × 10
−5 (%)
b
Disease liability
(case-control)
CYSLTR2 77.5 68.5 AKR1D1 72.5 36.5
MGEA5 84 79.5 AQP3 74 66.5
NF2 85.5 76.5 CAPNS1 74 64
PTPN11 83.5 71 EIF6 84 77.5
UGT1A1 72.5 55 FLT1 72.5 5
LYPD6 77.5 72.5
PCDHGA4 77 69.5
PRKCG 70 65
UGT1A1 71.5 55.5
Q1 CYSLTR2 62.5 45 FLT1 96.5 97.5
FLT1 100 92 SLC2A13 69.5 0
PTPN11 64.5 42.5
Q2 PIK3R1 66.5 29 VNN1 62 0
PTGIS 62.5 41.5
PTPN11 71.5 51.5
Listed genes were significant in at least 70% of replicates. Genes in boldface are the true causal genes in the simulation model.
a Percentage of replicates in which the gene was significantly associated with disease liability, Q1, or Q2 at the significance level of 0.05.
b Percentage of replicates in which the gene was significantly associated with disease liability, Q1, or Q2 at the significance level of 1.56 × 10
−5
Jung et al. BMC Proceedings 2011, 5(Suppl 9):S103
http://www.biomedcentral.com/1753-6561/5/S9/S103
Page 4 of 6of rare variant association depends on the collapsing
strategy used.
In addition to differences in the collapsing strategy,
our approach to analyzing each ethnic group versus the
combined sample group shows how variations in popu-
lation can affect the results. Six genes on average were
detected from each ethnic group. Few of the same
genes, whether they were false-positive associations or
true associations, were detected by the analysis of the
combined sample group versus the individual ethnic
groups. From the results of our analyses, we can also
s e et h a tt h et h r e ee t h n i cg r o u p sh a v eaw i d er a n g eo f
allele frequencies for some SNPs. Variants within the
same gene that have different allele frequencies should
not be collapsed into the same group to avoid a loss of
statistical power. The GAW17 simulation model did not
take population allele frequency differences into
account, and this could be the cause of much of the dis-
crepancy in the detection of genes using various collap-
sing approaches or analytic strategies. Therefore
ethnicity-specific analysis might be a better approach to
performing association studies of genome sequence data
than using the full combined sample group because
causal rare variants may have different frequencies in
different ethnic groups in real human populations.
In using our novel approach to identify rare variants
associated with disease traits, we found that 5 causal
genes (out of 35) in the simulation models were
detected with a reasonable power. However, we did not
detect many of the genes in the GAW17 answers as
being significant, for several reasons. First, our statistical
model does not take into account any pathway informa-
tion. In the simulation model the genes associated with
Q1 are from the vascular endothelial growth factor
(VEGF) pathway, and the genes associated with Q2 are
from the cardiovascular disease risk and inflammation
pathways, both of which influence disease liability. The
power to detect true causal variants might have been
improved if all rare variants within a pathway were col-
lapsed together into a single pathway variant indicator.
Second, the effect size of many of the “causal” variants
was quite small, thereby limiting power. Third, the
assumptions made by a zero-inflated Poisson model for
the collapsed rare variants might not be suitable for
some genes with only a few SNPs. In that case, one
might need to apply a zero-inflated binomial regression
Table 3 Genes significantly associated with disease liability for each ethnic group at the significance levels of 0.05 and
1.56 × 10
−5
Africans (n = 215) Europeans (n = 156) Asians (n = 321)
Gene Replicates
significant at
0.05 (%)
a
Replicates
significant at 1.56
×1 0
−5 (%)
b
Gene Replicates
significant at
0.05 (%)
a
Replicates
significant at 1.56
×1 0
−5 (%)
b
Gene Replicates
significant at
0.05 (%)
a
Replicates
significant at 1.56
×1 0
−5 (%)
b
CYSLTR2 84 71 CCNH 72 57 CHEK1 95.5 95.5
FER 77 50.5 CLPTM1 71 38 FLJ43860 72.5 64
FNDC3A 73 68 CYP17A1 74 65.5 IL4I1 74.5 53.5
NTRK1 71 59.5 GDNF 83 22 LRRC20 74.5 69.5
OR8J3 71.5 51.5 OR13A1 86.5 82.5 NF2 87.5 67.5
PTPN11 86.5 74 SPINK2 89.5 47
ST5 84.5 79.5
Listed genes were significant in at least 70% of replicates. None of the genes were true causal genes in the simulation model. Analysis is for all SNPs.
a Percentage of replicates in which the gene was significantly associated with disease liability at the significance level of 0.05.
b Percentage of replicates in which the gene was significantly associated with disease liability at the significance level of 1.56 × 10
−5.
Table 4 Power to detect causal genes (out of 35 genes) in the GAW17 simulation models using the combined sample
Trait All SNPs (nonsynonymous and synonymous) Nonsynonymous SNPs
Gene Power calculated at
significance level 0.05 (%)
Power calculated at
significance level 1.56 × 10
−5
(%)
Gene Power calculated at
significance level 0.05 (%)
Power calculated at
significance level
1.56 × 10
−5 (%)
Disease
liability
FLT1 100 92 PTK2 54.5 33.5
FLT1 96.5 97.5
Q1 FLT1 100 92 FLT1 96.5 97.5
KDR 56.5 0 KDR 54.5 0
Q2 VNN1 46.5 0 VNN1 62 0
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account the dispersion parameter of variance in the
model for consistent parameter estimation. Therefore
further research is needed to evaluate the zero-inflated
Poisson regression model for its ability to handle the
various characteristics of various rare variants.
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Table 5 Power to detect causal genes in the GAW17 simulation model as associated with disease liability using each
ethnic group
Africans (n = 215) Europeans (n = 156) Asians (n = 321)
Gene Power
calculated at
significance
level 0.05 (%)
Power calculated
at significance
level 1.56 × 10
−5
(%)
Gene Power
calculated at
significance
level 0.05 (%)
Power calculated
at significance
level 1.56 × 10
−5
(%)
Gene Power
calculated at
significance
level 0.05 (%)
Power calculated
at significance
level 1.56 × 10
−5
(%)
PIK3C3 58 32 PIK3C3 66.5 51.5 NRAS 43 33
SHC1 42 29.5
Analysis is for all SNPs.
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